Animal Health Biotechnology in European Union 2026: Industry Statistics & Trends

The animal health biotechnology industry in the European Union encompasses the research, development, and manufacturing of biological veterinary medicines, advanced therapeutics, and diagnostics for livestock and companion animals. The sector is moving rapidly toward preventative biologics and advanced gene therapies driven by rigorous regulatory standards that prioritize animal welfare and public health. This shift is exemplified by regional developments, such as the 274 available immunological drugs registered by industry bodies like pharma.be in Belgium in 2022 (pharma.be 2022 Report to Society), and a total EU-wide pipeline heavily supported by the European Commission's 2026 Biotech Act

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Animal Health Biotechnology in European Union industry cover?

The EU animal health biotechnology industry comprises entities dedicated to producing veterinary biological products, molecular diagnostics, and advanced therapy medicinal products (ATMPs). It focuses heavily on immunological veterinary medicinal products, recombinant proteins, and gene therapies designed to prevent and treat animal diseases. This sector specifically excludes traditional chemical-based pharmaceuticals, positioning itself as a high-technology subset of broader veterinary medicine.

• •Encompasses targeted innovations like monoclonal antibodies, mRNA-based animal vaccines, and stem cell therapies.
• •Scope explicitly outlined under the European Commission's 2026 regulatory guidelines separating novel biologicals from chemical pharmaceuticals.
• •Driven by the 'One Health' framework, recognizing the interdependence of human health, animal health, and the environment.

Who operates in the industry and how is it structured?

The market is structured around a combination of global multinational conglomerates with extensive European operations and specialized biotechnology clusters across EU member states. These operators manage advanced manufacturing facilities that must comply with strict Union standards for manufacturing biological products. Cooperation between commercial laboratories and public research universities forms the backbone of early-stage biological pipelines.

• •Includes dedicated animal health divisions of major global life sciences entities operating within the European single market.
• •Relies heavily on centralized validation from the European Medicines Agency (EMA) and its Committee for Veterinary Medicinal Products (CVMP).
• •National ecosystems, such as Belgium's biopharmaceutical sector, recorded 4,005 industry-related jobs in 2021 (pharma.be 2022 Report to Society).

What drives demand in the industry?

The primary drivers for animal health biotechnology in the EU are the rising prevalence of transboundary animal diseases and the strict regulatory push to curb antimicrobial resistance (AMR). European agricultural policies strongly favor preventative vaccination strategies over therapeutic antibiotic use in livestock production. Additionally, increasing consumer expenditure on companion animal healthcare accelerates the demand for advanced, non-invasive therapeutic options.

• •Persistent threats from zoonotic diseases like highly pathogenic avian influenza necessitate rapid-response vaccine biotechnology.
• •The EU Animal Health Law mandates preventative disease control, heavily incentivizing the adoption of novel immunological solutions.
• •Rising demand for companion animal longevity treatments, duplicating human oncology and chronic disease biotech applications.

Who are the notable companies in the industry?

The European single market features robust competition among premier public multinational corporations that maintain prominent research and commercial operations across multiple EU member states. These entities compete heavily on pipeline innovation, seeking centralized market authorizations from the EMA to commercialize biologicals continent-wide. The landscape is characterized by strategic alliances between these large-cap public firms and agile, niche biotechnology laboratories.

• •Boehringer Ingelheim Vetmedica (operating as part of the prominent European-based Boehringer Ingelheim group).
• •Zoetis Inc. (maintaining extensive European manufacturing and R&D hubs, including major sites in Belgium and France).
• •Merck & Co., Inc. (operating as MSD Animal Health within the EU, with significant European biological manufacturing footprints).
• •Elanco Animal Health Incorporated (actively marketing a diverse portfolio of biological and diagnostic solutions across Europe).

What are the recent trends and outlook?

The industry is experiencing a profound transformation marked by regulatory simplification initiatives and an aggressive push toward eliminating animal testing in product development. The European Commission's introduction of the landmark Biotech Act framework aims to eliminate ecosystem fragmentation and streamline administrative pathways for biotech innovations. Concurrently, new roadmaps are driving the sector toward in vitro and digital modeling to replace traditional target animal safety trials where scientifically feasible.

• •The European Commission's May 2026 Staff Working Document (SWD(2026) 450) outlines targeted actions to boost biomanufacturing capacity.
• •A June 2026 EU roadmap (SWD(2026) 144) targets a transition to Next-Generation Risk Assessment (NGRA), though biologicals maintain specific exemptions for final-stage safety.
• •An increasing industry-wide pivot toward mRNA platforms to shrink vaccine development timelines for emerging livestock mutations.

How is the industry regulated?

Compliance within the EU animal health biotechnology sector is governed by stringent centralized legislation designed to guarantee safety, efficacy, and environmental protection. Manufacturers must navigate intricate authorization processes managed via the EMA's centralized procedure to achieve single-market access. Compliance rules are heavily influenced by harmonized frameworks that dictate manufacturing quality control and post-market safety tracking.

• •Governed by the overarching EU Animal Health Law, which emphasizes comprehensive surveillance and disease categorization.
• •Requires strict adherence to veterinary Good Manufacturing Practice (GMP) specific to biological and immunological substances.
• •Mandatory reporting of post-market adverse events through the centralized Union Pharmacovigilance Database system.

Government, statistical and trade sources used for this Claight analysis.

• European Commission Staff Working Document on the Biotech Act (SWD(2026) 450) ·
• European Commission Roadmap on Phasing Out Animal Testing (SWD(2026) 144) ·
• European Medicines Agency (EMA) Committee for Veterinary Medicinal Products (CVMP) Guidelines 2025/2026 ·
• pharma.be Report to Society 2022 ·
• AnimalhealthEurope Corporate and National Membership Registers 2026